Systemic cancer modalities include Conventional cytotoxic therapy (eg, fluorouracil, methotrexate, daunorubicin, cyclophosphamide) Hormonal therapy (for selected cancers, eg, prostate, breast, endometrium) Immune therapy, including monoclonal antibodies, interferons, biologic response modifiers, tumor vaccines, and cell therapies (for many different types of cancer) Differentiating drugs such as retinoids (for acute promyelocytic leukemia) and isocitrate dehydrogenase-2 (IDH2) inhibitors (for acute myeloid leukemia) Targeted drugs that exploit the growing knowledge of genomics and cellular and molecular biology (eg, imatinib for chronic myeloid leukemia) Often, modalities are combined to create a treatment program that is appropriate for the patient, based on patient and tumor characteristics as well as patient preferences.